Login / Signup

Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.

Mengfei LuCathryn M LewisMatthew Traylor
Published in: BMC medical genomics (2017)
23andMe reports provide some useful pharmacogenetics information, mirroring clinical tests that are in standard use. Other tests are unspecific, providing limited guidance and may not be useful for patients without professional interpretation. Nevertheless, DTC companies like 23andMe act as a powerful intermediate step to integrate pharmacogenetic testing into clinical practice.
Keyphrases
  • end stage renal disease
  • clinical practice
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • health information
  • peritoneal dialysis
  • healthcare
  • patient reported outcomes